Cinryze and Pregnancy
It is unknown what may happen if Cinryze is used during pregnancy, as no studies have been done on this. Due to the unknown risks, the manufacturer recommends that pregnant women only use this drug if it is clearly necessary. If you become pregnant during treatment, talk to your healthcare provider about whether you should continue using Cinryze.
Cinryze® (C1 esterase inhibitor) is a prescription medicine used to treat people with hereditary angioedema (HAE), a rare but serious condition of the immune system that is passed through families. This medication may not be safe for use during pregnancy, although the full risks are not entirely known.
The U.S. Food and Drug Administration (FDA) uses a category system to classify the possible risks to a fetus when a specific medicine is taken during pregnancy. Cinryze is classified as a pregnancy Category C medication.
Pregnancy Category C is given to medicines that have not been studied in pregnant humans but do appear to cause harm to the fetus in animal studies. Also, medicines that have not been studied in any pregnant women or animals are automatically given a pregnancy Category C rating.
Cinryze is a pregnancy Category C medication because it has not been studied in pregnant women or animals. Therefore, at this time it is not known whether this drug would harm an unborn child.
The manufacturer recommends the medication only be given to pregnant women if it is clearly needed. If you become pregnant during treatment with Cinryze, or wish to become pregnant, discuss this with your healthcare provider. Because hereditary angioedema attacks are potentially life-threatening, there may be times when a healthcare provider recommends treatment during pregnancy despite the unknown risks.